Work

Supplementary Table S3 from Second Primary Malignancy Risk in Patients with Multiple Myeloma Receiving CAR T-cell Therapy or Other Systemic Anticancer Treatments: A Real-World Comparative Study

Year: 2026

Type: supplementary-materials

Abstract: Table S3. Weighted cumulative incidence of SPM with death as competing risk in patients with multiple myeloma receiving CAR T therapy or other SACT and remained at-risk at Month 2, stratified by receipt of post-baseline bone marrow examinations by Month 2

DOI: 10.1158/1078-0432.33775988

Authors: Attaya Suvannasankha, Mengying Li, Omonefe Omofuma, Christian Hampp, Matthew Phelan, Alexander Breskin, Ping Shao, Tito Roccia, Nandita Mukherjee, Anju Shrestha, Daniel Lee, Jacob Glass, Glenn S. Kroog, Karen Rodriguez Lorenc

Topic: Multiple and Secondary Primary Cancers

Subfield: Epidemiology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

OpenAlex ID: W7213347673

Cites:

Cited by:

Related to: